Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $1.90M |
| Gross Profit (TTM) | 303,000 |
| EBITDA | $-9.58M |
| Operating Margin | -359.20% |
| Return on Equity | -98.20% |
| Return on Assets | -52.30% |
| Revenue/Share (TTM) | $3.43 |
| Book Value | $8.37 |
| Price-to-Book | 3.15 |
| Price-to-Sales (TTM) | 8.28 |
| EV/Revenue | 7.69 |
| EV/EBITDA | 0.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -43.20% |
| Shares Outstanding | 668,760 |
| Float | 168,030 |
| % Insiders | 21.70% |
| % Institutions | 70.86% |
Volatility is currently expanding
Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer's patients anticipated by year-end 2027 or first quarter of 2028
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CYCN and any ticker you trade — then tracks every position and per-strategy win rate.
